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Comment 
     The rising level of non-treatable (antimicrobial 
resistant) bugs has captured global attention. The O’Neill 
commission warned that failure to act would result in an 
additional 10 million lives lost each to malaria, HIV, TB, 
and certain bacterial infections by 2050, at a cost to the 
world economy of 100 trillion USD [1]. On 21st Sept 2016, 
the United Nations (UN) assembly approved the World 
Health Organisation (WHO) Global action plan (GAP) 
against antimicrobial resistance (AMR) and urged all 
member nations to act [2]. However, the contents of the 
plan and strategies thereof are dominated by what the 
global north perceives to be the drivers of AMR and 
consequently how it should be fought. It is crucial that the 
understanding of AMR and efforts to fight it are 
contextualised, otherwise the plan will fail to realise its 
goals. For instance, antibiotic abuse in developed world 
may be due to overuse of a variety of antibiotics because 
they are available while in developing world it could be 
due to overuse of the same class of antibiotics because 
better antibiotics aren’t available.  
 
     Nationally-led action against AMR cannot be more 
critical given the fact that there are huge variations in 
health systems capacities and the different pressures on 
the economic purse between developed and developing 
countries [3]. At the 6th East African health and scientific 
research conference (28th – 31st March 2017), over 1000 
East Africans gathered in Bujumbura, Burundi to discuss 
and shape the healthcare agenda for the region, the East 
African Community (EAC). Pertinent to the agenda was 
drawing action plan to address AMR in the region. A 
symposium was held that examined the region’s 
antimicrobial agents’ usage practices, the AMR burden 
and made policy recommendations for the EAC action 
against AMR. 
 
     Despite existence of medicines regulations, 
antimicrobial drugs are still accessible without 
prescription in the EAC. Most prescriptions occur without 
following the national guidelines or diagnosis to support 
the prescription decisions. It is easy to think that this is 
simply negligence or lack of laboratory capacity but it is 
not as simple as that. During a prescription behaviour 
study in one of the EAC countries, a doctor was asked why 
they prescribe without laboratory diagnosis, he answered, 
‘the laboratory never returns test results’. When the 
laboratory manger was asked, they said the clinic never 
asks for tests. Doctor, the laboratory says you never ask 
for tests, well, we don’t trust the laboratory to deliver the 
tests. Laboratory manager, why is it that the laboratory is 
not trusted for performing the required tests, well, the 
hospital management hardly allocates budget for us to 
conduct the tests [4]. This back and forth blame game 
demonstrates that though global, the challenges have a 
unique local context that must be considered when 
developing the agenda for action against AMR. Likewise, 
there are many underlying national and regional factors 
why regulators (policy enforcers) fail to stop misuse of 
medicines. 
 
     On the human – animal interface, livestock keepers feel 
neglected by the health system and so have taken matters 
in their own hands by procuring antimicrobials from open 
market sales and administering to their animals 
themselves. For instance, 87-100% of the Bahima and 
Basongora pastoralists in western Uganda and 64% of the 
Maasai in southern Kenya and northern Tanzania 
administered antibiotics without consulting Veterinary 
practitioner [5]. No intervention would be successful 
without a thorough examination of this behaviour and its 
impact on the emergence and spread of AMR. In this case, 
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 a national – community-led agenda is critical. The driving 
factors are so intricate and require a contextualised 
response [6]. The answers lie with the communities 
themselves [3]. In this respect, the symposium was asked 
to outline the most important aspects they would like to 
see in the EAC policy on AMR. 107 recommendations 
were received and grouped into six thematic areas: 
streamlining health system governance and financing, 
increasing awareness, strengthening and harmonizing 
medicines regulatory framework, training, laboratory 
capacity enhancement, and research and development for 
new diagnostics, antimicrobials and vaccines. Over 50% 
of the recommendations highlighted governance focusing 
on streamlining to stamp out inefficiency and corruption. 
Increasing AMR awareness through public and school 
education was the 2nd popular recommendation. This 
means dealing with the basics, that is, increasing health 
system efficiency and educating the masses could solve a 
large part of the AMR problem without necessarily 
spending huge sums of money. The agenda for fighting 
AMR must be led from where the answers are, from the 
grassroots community to the nations and to the world at 
large. 
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